During this discussion, experts will share methods for identifying promising drug targets and biomarkers by leveraging linked clinico-genomic data in advancing therapeutic development and its application from research to clinical care.
In a rapidly evolving drug development landscape, it’s becoming increasingly important to leverage precision approaches to help characterize sub-populations of patients and uncover individual genetic drivers of safety and response – especially for germline disorders including cardiovascular. Genetic data combined with linked longitudinal clinical data, including full labs & patient vitals/demographics, has been shown to optimize target discovery and address the challenges of 'precision’ medicine development.
During this discussion, experts will share methods for identifying promising drug targets and biomarkers by leveraging linked clinico-genomic data in advancing therapeutic development and its application from research to clinical care.
Insights offered in this discussion:
Examine how linked clinico-genomic data can help better understand complex disease mechanisms to enable the development of targeted therapeutics with better safety and efficacy profiles
Leverage these datasets to support the identification and stratification of diverse patient populations that are more likely to respond to targeted therapeutics
Understand the health research perspective on how genetic medicines are translated into clinical care especially in cardiovascular diseases
Explore real-world examples where precision medicine has impacted drug development
Offered Free by: Helix See All Resources from: Helix